New weekly shot could help adults with growth hormone deficiency
NCT ID NCT07551804
First seen Jun 27, 2026 · Last updated Jul 23, 2026 · Updated 2 times
Summary
This Phase 2a trial tests a new long-acting growth hormone injection called inpegsomatropin in 36 adults with growth hormone deficiency. Participants receive different doses or a placebo once a week to check safety and how well the drug works. The goal is to see if this weekly shot can improve body composition and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Inpegsomatropin (a long-acting growth hormone injection)
- What this could lead to
- If successful, this could provide a once-weekly treatment option for adults with growth hormone deficiency, potentially improving body composition and quality of life.
- What could go wrong
- This is an early Phase 2a trial with only 36 participants, so results may not apply to everyone. The drug may cause side effects or fail to show meaningful benefit over placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT GROWTH HORMONE DEFICIENCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Huashan Hospital, Fudan University
RECRUITINGShanghai, China
-
Peking University First Hospital
RECRUITINGBeijing, China
-
The First Affiliated Hospital of Henan University of Science and Technology
RECRUITINGHenan, China
-
The First Affiliated Hospital of Xiamen University
RECRUITINGXiamen, China
-
The Second Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGZhejiang, China
-
West China Hospital, Sichuan University
RECRUITINGSichuan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Weekly shot could replace daily hormone injections for adults
- Could growth hormone ease gulf war illness symptoms?
- Japan study tracks Sogroya's Long-Term safety in severe hormone deficiency
- New growth hormone drug enters first human tests
- New study tracks Sogroya's safety over a decade in growth hormone deficiency
- Weekly shot shows promise for adult growth hormone deficiency in Long-Term trial